Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
11:28am, Thursday, 19'th Feb 2026
Bristol-Myers Squibb Company ended 2025 and started this year on a high note. On February 6, its stock reached a 52-week high of $63.3. One of the reasons BMY is once again becoming a Wall Street favo
FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma
12:36pm, Wednesday, 18'th Feb 2026
FDA accepts and grants priority review to Bristol Myers' NDA for iberdomide combo in relapsed or refractory multiple myeloma. A decision is due on Aug. 17, 2026.
This State Has More Millionaires Per Capita Than Any Other
09:21pm, Tuesday, 17'th Feb 2026
There are many ways to describe America. Some might call it a veritable patchwork of diverse cultures and social strata. That's a fancy way of saying that prosperity is concentrated in some U.S. state
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?
11:02am, Tuesday, 17'th Feb 2026
BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or Refractory Multiple Myeloma.
Atria Investments Inc Lowers Position in Bristol Myers Squibb Company $BMY
04:36am, Sunday, 15'th Feb 2026
Atria Investments Inc decreased its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 11.7% in the undefined quarter, according to its most recent Form 13F filing with the Securities a
CENTRAL TRUST Co Lowers Position in Bristol Myers Squibb Company $BMY
03:56am, Saturday, 14'th Feb 2026
CENTRAL TRUST Co cut its stake in shares of Bristol Myers Squibb Company (NYSE: BMY) by 7.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities an
John Rogers' Strategic Moves: Sphere Entertainment Co Sees Significant Reduction
02:00pm, Friday, 13'th Feb 2026
Exploring the Fourth Quarter 2025 13F Filing John Rogers (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providing insigh
Caisse Des Depots ET Consignations Sells 21,113 Shares of Bristol Myers Squibb Company $BMY
06:21am, Thursday, 12'th Feb 2026
Caisse Des Depots ET Consignations trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 36.7% in the third quarter, according to the company in its most recent Form 13F filing
2 Urgent Sells And 2 No Brainer Dividend Buys
04:06pm, Wednesday, 11'th Feb 2026
One thing I've learned is the pendulum always swings. It is in our best approach to sell high and buy low. This has worked well for us, as our returns suggest.
Best Stocks Outside The Mag 7 To Balance Growth And High Yield
04:00pm, Wednesday, 11'th Feb 2026
Markets in 2026 are rewarding selectivity rather than size alone. Mega-cap leadership has narrowed, volatility has resurfaced, and investors are searching for a framework that can adapt to rotation. A
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Wednesday, 11'th Feb 2026
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?
12:10pm, Tuesday, 10'th Feb 2026
BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.
Wesbanco Bank Inc. Reduces Position in Bristol Myers Squibb Company $BMY
03:46am, Tuesday, 10'th Feb 2026
Wesbanco Bank Inc. trimmed its stake in Bristol Myers Squibb Company (NYSE: BMY) by 5.5% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC)
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
11:30am, Monday, 09'th Feb 2026
BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.
